

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCY United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/681,410	10/08/2003	Si-Yi Chen	053665-5009-02	7428	
28977	7590 09/14/2006		EXAM	EXAMINER	
MORGAN, LEWIS & BOCKIUS LLP 1701 MARKET STREET PHILADELPHIA, PA 19103-2921			SALIMI, ALI REZA		
			ART UNIT	PAPER NUMBER	
			1648		
			DATE MAILED: 09/14/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/681,410	CHEN ET AL.				
Office Action Summary	Examiner	Art Unit				
	A R. Salimi	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONEI	ely filed the mailing date of this communication. 0 (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 08 Oc	ctober 2003.					
	<u> </u>					
3) Since this application is in condition for allowan	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>120-199</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) ☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 120-199 are subject to restriction and/or election requirement.						
Application Papers	•					
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)	_					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal Pa					
Paper No(s)/Mail Date 6) ☐ Other:						

Application/Control Number: 10/681,410 Page 2

Art Unit: 1648

DETAILED ACTION

Response to Amendment

The receipt of preliminary amendment of 10/08/2003 is acknowledged. Claims 1-119 have been canceled. Claims 120-199 have been added and are pending.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 120-143, 198, drawn to method of identifying isolated polynucleotide encoding antigen, classified in class 435, subclass 91.1.
- II. Claims 144-146, drawn to expression vector and vaccine, classified in class 424, subclass 199.1.
- III. Claims 147-153, drawn to cells, classified in class 435, subclass 325.
- IV. Claim 154, drawn to a vaccine, classified in class 530, subclass 300.
- V. Claim 155, drawn to isolated polynucleotide, classified in class 514, subclass 44. (Please note if this group is selected further select one sequence to be examined on the merits, and amend the claims accordingly, see below for explanation)
- VI. Claims 156-158, drawn to polypeptide and vaccine, classified in class 536, subclass 23.72. (Please note if this group is selected further select one sequence to be examined on the merits, and amend the claims accordingly, see below for explanation)
- VII. Claims 159-182, 199, drawn to method of identifying an antigen, classified in class 435, subclass 7.1.
- VIII. Claims 183-185, drawn to expression vector and vaccine, classified in class 435, subclass 320.1.
- IX. Claims 186-192, drawn to cells, classified in class 435, subclass 343.2.
- X. Claim 193, drawn to vaccine, classified in class 424, subclass 204.1.

Art Unit: 1648

XI. Claim 194, drawn to isolated polynucleotide, classified in class 435, subclass 91.33. (Please note if this group is selected further select one sequence to be examined on the merits, and amend the claims accordingly, see below for explanation)

Page 3

XII. Claims 195-197, drawn to polypeptide and vaccine, classified in class 930, subclass 220. (Please note if this group is selected further select one sequence to be examined on the merits, and amend the claims accordingly, see below for explanation)

The inventions are distinct, each from the other because of the following reasons:

Inventions of Groups I-XII are mutually exclusive and patentably distinct methods and products. Products are structurally and functionally different and can be by different methods and have different uses and delineate different results in addition to having different effect on interaction, antigenicity and immune response. In addition, various methods have different uses, and have different modes of operation as well as functions. The examination of all groups would require different searches in the U.S. Patent Shoes and scientific literature and would require the consideration of different patentability issues (MPEP § 806.04, MPEP § 808.01).

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

Upon election any one of Groups V, VI, XI or XII Applicants are additionally required to elect a single Sequence identified by a specific sequence identification number, as indicated

Application/Control Number: 10/681,410

Art Unit: 1648

above as they apply to group(s). The recited sequences have different structures one from other and the search for the sequences would be unduly burdensome. This requirement is not to be construed as a requirement for an election of species, since each of the sequence(s) constitutes an independent and patentably distinct invention.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1648

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to A. R. Salimi whose telephone number is (571) 272-0909. The examiner can normally be reached on Monday-Friday from 9:00 Am to 6:00 Pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, can be reached on (571) 272-0974. The Official fax number is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A. R. Salimi

09/11/2006

